Revlimid® Capsules Drug Use-results Surveillance (Relapsed or Refractory ATLL)

Last updated: March 28, 2025
Sponsor: Celgene
Overall Status: Completed

Phase

N/A

Condition

Lymphoma

Treatment

Revlimid

Clinical Study ID

NCT03098589
NIS-Celgene-JP-PMS-004
  • Ages > 18
  • All Genders

Study Summary

To understand the safety and efficacy of Revlimid® Capsules 2.5 mg and 5 mg (hereinafter referred to as Revlimid) under actual conditions of use in patients with relapsed or refractory adult T-cell leukemia lymphoma (hereinafter referred to as relapsed or refractory Adult T-cell Leukemia Lymphoma (ATLL)).

  1. Planned registration period 3 years

  2. Planned surveillance period 4 years and 6 months after a month after the approval for partial changes in the approved items is granted for relapsed or refractory ATLL

Eligibility Criteria

Inclusion

Inclusion Criteria:

  • Relapsed or Refractory Adult T-cell Leukemia Lymphoma

Exclusion

Exclusion Criteria:

  • N/A

Study Design

Total Participants: 1149
Treatment Group(s): 1
Primary Treatment: Revlimid
Phase:
Study Start date:
May 30, 2017
Estimated Completion Date:
September 18, 2020

Connect with a study center

  • ASO KK Iizuka Hospital

    Iizuka, Fukuoka 820-8505
    Japan

    Site Not Available

Not the study for you?

Let us help you find the best match. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.